CDC42 and central nervous system cancer: An increase in R (-)-2-hydroxyglutarate in gliomas harboring IDH mutations has been found to prevent the association of MLK3 with Cdc42 and further inhibit the activity of MLK3, which may be one of the reasons for the better prognosis in patients with IDH-mut gliomas (26, 27).